Results 41 to 50 of about 16,038 (249)

Convalescent plasma therapy for Covid-19: A systematic review

The National Medical Journal of India, 2020
Covid-19 has emerged as a pandemic affecting more than 20 million people till date with few, if any, proven therapy. Convalescent plasma (CP) containing antibodies against the virus has been used with some success. We did a systematic review to synthesize the available data on CP therapy for treatment of Covid-19 to study the efficacy and safety ...
Tulika, Seth, Arunmozhimaran, Elavarasi, Ranjit Kumar, Sahoo, , Shalimar, Karan, Madan, Neeraj, Nischal, Manish, Soneja, Pramod, Garg, Kameshwar, Prasad, Atul, Sharma   +9 more
openaire   +3 more sources

Convalescent plasma therapy for Covid 19 - A perspective

Hematology & Transfusion International Journal, 2021
Convalescent plasma therapy has been used for years. However, its use in Covid-19 is still experimental. While it can be life-saving, its efficacy as well as risks need to be evaluated to establish this as a therapeutic option. Also, for this proper infrastructure and adequate facilities need to be in place before embarking on this journey.
Asad Mahmood, Rafia Mahmood, Maria Khan, Sadia Ali, Nabeela Khan, Syed Raza Jaffar   +5 more
openaire   +1 more source

Reviewing the Ethical Concerns of the Convalescent Plasma Therapy in COVID-19 [PDF]

Journal of Laboratory Physicians, 2021
AbstractThe understanding of coronavirus disease 2019 (COVID-19) is evolving periodically. There is also a marked increase in COVID-19 patients’ demand for the provision of COVID-19 convalescent plasma (CCP) therapy. With the review of the literature, the stage of speculation is quickly moving towards conformity, with the interim guidelines given by ...
Manish Raturi, Mansi Kala, Kunal Das, Anuradha Kusum   +3 more
openaire   +2 more sources

Convalescent Plasma for the Treatment of Severe COVID‐19 Infection in Cancer Patients

Cancer Medicine, 2020
Background Patients with malignancy are particularly vulnerable to infection with Severe Acute Respiratory Disease‐Coronavirus‐2 (SARS‐CoV‐2) given their immunodeficiency secondary to their underlying disease and cancer‐directed therapy. We report a case
Douglas Tremblay, Carina Seah, Thomas Schneider, Sheena Bhalla, Jonathan Feld, Leonard Naymagon, Bo Wang, Vaibhav Patel, Tomi Jun, Thomas Jandl, Farah Rahman, Sean T. H. Liu, Judith A. Aberg, Nicole Bouvier, The Mount Sinai Health System Convalescent Plasma Team   +14 more
doaj   +1 more source

Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals

mBio, 2020
In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to coronavirus disease 2019 (COVID-19) patients.
Guillaume Beaudoin-Bussières, Annemarie Laumaea, Sai Priya Anand, Jérémie Prévost, Romain Gasser, Guillaume Goyette, Halima Medjahed, Josée Perreault, Tony Tremblay, Antoine Lewin, Laurie Gokool, Chantal Morrisseau, Philippe Bégin, Cécile Tremblay, Valérie Martel-Laferrière, Daniel E. Kaufmann, Jonathan Richard, Renée Bazin, Andrés Finzi   +18 more
doaj   +1 more source

A male Covid-19 convalescent plasma donor with long existence of SARS-Cov-2 antibodies: a case report

JKKI (Jurnal Kedokteran dan Kesehatan Indonesia), 2023
Covid-19 Convalescent Plasma (CCP) was one of alternative therapy for Covid-19 patients. The use of convalescent plasma as an adjunct therapy must consider its efficacy, benefits, and risk, both for the patient and the donor.
Teguh Triyono, Usi Sukorini, Andri Christianalusi, Sri Mulatsih, Hans Vrielink   +4 more
doaj   +1 more source

The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report

Case Reports in Women's Health, 2020
Summary: Remdesivir is a novel therapeutic with known activity against SARS CoV-2 and related coronaviruses. Remdesivir, as well as convalescent plasma therapy, are currently under investigation as potential therapies for patients with Coronavirus ...
Jonathon Anderson, Jordan Schauer, Suzanne Bryant, Cornelia R. Graves   +3 more
doaj   +1 more source

The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients

Medicina, 2021
Background and Objectives: On 24 March 2020, the United States Food and Drug Administration (FDA) announced the approval of convalescent plasma therapy for critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an ...
Livius Tirnea, Felix Bratosin, Iulia Vidican, Bianca Cerbu, Mirela Turaiche, Madalina Timircan, Madalin-Marius Margan, Iosif Marincu   +7 more
doaj   +1 more source

Mortality Benefit of Convalescent Plasma in COVID-19: A Systematic Review and Meta-Analysis

Frontiers in Medicine, 2021
Importance/Background: With a scarcity of high-grade evidence for COVID-19 treatment, researchers and health care providers across the world have resorted to classical and historical interventions. Immunotherapy with convalescent plasma (CPT) is one such
Vikas Bansal, Kiran S. Mahapure, Ishita Mehra, Abhishek Bhurwal, Aysun Tekin, Romil Singh, Ishita Gupta, Sawai Singh Rathore, Hira Khan, Sohiel Deshpande, Shivam Gulati, Paige Armaly, Mack Sheraton, Rahul Kashyap   +13 more
doaj   +1 more source

Use of convalescent serum reduces severity of COVID-19 in nonhuman primates

Cell Reports, 2021
Summary: Passive transfer of convalescent plasma or serum is a time-honored strategy for treating infectious diseases. Human convalescent plasma containing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently being
Robert W. Cross, Abhishek N. Prasad, Viktoriya Borisevich, Courtney Woolsey, Krystle N. Agans, Daniel J. Deer, Natalie S. Dobias, Joan B. Geisbert, Karla A. Fenton, Thomas W. Geisbert   +9 more
doaj   +1 more source